FTSE 100 opens higher on vaccine news & Biden transition

0
The FTSE 100 opened higher on Tuesday as markets continued to react well to the ongoing vaccine news. The FTSE 100 opened 55 points higher or 0.87% to 6389 in early trading, which was boosted by growth in travel stocks, energy companies and hospitality firms. In Europe, markets also opened higher. Germany’s DAX increased by 0.85% and France’s CAC was up 1%. Fiona Cincotta at Gain Capital said: “The dominant driving force behind the market has been progress in vaccine development.” Top risers on Tuesday morning included Rolls-Royce (+6.3%), airline group IAG (+4.5%), and oil giant BP (+3.6%). The FTSE 250 also saw gains at the opening bell. Shares in TUI gained almost 10%. Markets were also cheered by signs that US President Donald Trump is accepting that he will be replaced by Joe Biden in January.

“After much delay the General Services Administration has signalled that Joe Biden and his team can begin the formal transition process ahead of January’s inauguration, a move that Donald Trump gave his approval despite insisting he will continue with his unfounded claims of voter fraud in order to overturn the result,” said Connor Campbell from Spreadex.

“The key thing for the markets is that the smoother the transition, the easier it will be in theory for the new administration to hit the ground running in January – vitally needed given the out-of-control American covid-19 situation, and the planning needed for a nationwide vaccine rollout.”

Compass Group returns to Q4 profit, shares rise

Compass Group shares (LON: CPG) were up almost 5% on Tuesday morning after the group shares full-year results ending 30 September. After a “challenging” year for the group, the FTSE 100 firm returned to profit in Q4 thanks to mitigating costs, increasing liquidity, and strengthening the balance sheet. Revenue fell 18.8% from £24.8bn in 2019 to £20.2bn, whilst operating profit plunged 69.7% to £561m. The group started the year with strong performance, however, once the pandemic hit had to close half of its business. In the fourth-quarter, Compass was able to return to profitability and is now cash neutral. “2020 was a challenging year for Compass. I am extremely proud of how the organisation responded to the pandemic,” said chief executive, Dominic Blakemore. “We began the year on track to deliver our strongest performance ever, and over the course of a fortnight in March, we saw the containment measures to stop the spread of COVID-19 close half of the business. We rapidly enhanced our health and safety protocols, mitigated our costs, increased our liquidity and strengthened our balance sheet. “Through the summer, our performance began to improve slowly as we helped clients in Education and Business & Industry return to schools and offices safely. Importantly, in the fourth quarter we returned the business to profitability and are now cash neutral. This was achieved mainly through contract renegotiations to reflect the difficult trading environment, continued discipline in terms of costs and some improvement in volumes. We are executing at pace and expect the underlying operating margin in the first quarter of 2021 will be around 2.5%.” Looking forward, the group is preparing for a challenging trading environment and is adapting operations to improve the offer, increase flexibility and manage costs. Compass Group shares (LON: CPG) are trading +4.39% at 1.402,50 (0903GMT).

Pets at Home reveals “exceptional” demand over lockdown

0
Pets at Home (LON: PETS) has reported a total group revenue growth of 5.1% to £574.4m in the six months to October. Thanks to an “exceptional period of demand”, the group revealed a 4.2% jump in sales compared to the same period a year earlier. The FTSE 250 firm said in a trading update that it has adapted operations well to be able to continue providing pet care to customers with minimal disruption. The group has maintained an interim dividend per share of 2.5p. Looking forward, Pets at Home anticipates full-year underlying pre-tax profit to be in line with the prior year. Peter Pritchard, the chief executive of the group, said: “In spite of the ongoing and wide-ranging impact of COVID-19, there is much to be optimistic about. The market in which we operate remains resilient, with recent changes to our work and leisure patterns supporting rising levels of pet ownership, a good proxy for future growth in both the underlying market and our business. “We adapted our operations rapidly post the onset of the pandemic, and our focus on customer acquisition is underpinning market share gains across all channels and strong growth in our VIP and Puppy and Kitten clubs, thereby increasing the long-term opportunity of using data-driven, joined-up solutions across our range of products and services to drive customer share of wallet and lifetime value. “We are introducing new ways to meet our customers’ needs across all channels, making pet care as affordable, convenient, engaging and flexible as possible, and our customer-centric pet care platform, underpinned by the most extensive and unique proprietary pet dataset in the UK and a true omnichannel backbone, provides us with significant competitive advantages. “While we will continue to remain focused and agile in our execution, we are, more than ever, confident in the resilience and longevity of our pet care platform,” he added. Pets at Home shares (LON: PETS) are trading -7.35% at 388,20 (0840GMT).

Aviva shares optimistic on sale of shareholding in Italian business

Shares at British multinational insurance agency Aviva plc (LON:AV) bounced more than 2% on Monday evening following the news that the firm is set to sell its entire 80% shareholding in Italian life insurance venture Aviva Vita to its partner UBI Banca for €400 million in cash. The move is part of the firm’s new CEO – Amanda Blanc’s – broader plans to refocus its portfolio on more profitable divisions and shore up its finances since she took over in July. It comes just two months after Aviva sold its Singapore arm to a consortium of buyers for £1.6 billion in September. Although still subject to customary closing conditions, including regulatory approval, the move is expected to be completed in the first half of 2021 and should see the company’s net asset value increase by £100 billion. As part of the deal, Aviva also said that a €40 million loan provided by Aviva Italia Holding to Aviva Vita would be repaid in full at completion. It also represents a multiple of 8.4 times Aviva Vita’s 2019 IFRS profit, the firm said, and would increase the company’s capital surplus by 200 million pounds. CEO Amanda Blanc hailed the company’s news as an important step forward in the restructuring process: “The sale of Aviva Vita is another important step forward as we reshape our portfolio and follows the recent announcement of the majority sale of our Singaporean business. We will continue to be decisive as we seek to transform Aviva for the benefit of our shareholders”. Aviva Vita’s post-tax profit was £523 million in 2019, and it did not pay a dividend. The gross assets of Aviva Vita were £16.3 billion as of June 2020.

UBI Banca was already Aviva’s business partner, but the money it is now ploughing into the acquisition could help the firm pay off some of its outstanding debt and shore up liquidity.

Analysts have also speculated that the sale might help avert a widely-expected trimming of Aviva’s high dividend, which currently sits at 2.93%.

Alan Devlin, from Shore Capital Markets, said that analysts are expecting the dividend to be cut by about 30% – potentially by this Thursday – when Aviva is set to hold an investor day event.

But he added: “If the company can deploy the proceeds from the asset sales then the company can partially or indeed fully protect the dividend”.

A further update is expected from the firm on Thursday this week, when Blanc is expected to elaborate on her strategic plan for the group.

Aviva’s share price jumped 2.08% to 324.60p on market close on Monday 23/11/2020, edging closer to its annual high of 326.20p. The firm has enjoyed a rather smooth year despite widespread market turbulence due to the Covid-19 pandemic, with shares up 34.18% over the past 6 months. Its P/E ratio stands at 4.98 and its market capitalisation is a healthy £12.75 billion.

Xpeng – the Tesla rival whose shares have rallied 315% in two months

Chinese electric vehicle manufacturer Xpeng (NYSE:XPEV) watched its shares climb by around 25% on Monday, following news that it had made a significant tech announcement, and released a limited-edition model of its P-7 Sedan at the Guangzhou auto show. Having posted positive earnings last Friday, and seen its shares rise more than 10%, the company also announced that it had produced more than 10,000 of its smart EV P7 models in October. This production announcement was ahead of expectations, and will help cement the company’s credibility versus the likes of competitors such as NIO, Nikola Corp, Lucid, and of course, Tesla. During the same auto show that it unveiled the limited edition P7 model, Xpeng also announced that it had upgraded its driver-assist tech for its 2021 production models, and they will now feature lidar sensors. These sensors are part of a new system, described by the company as the “next-generation autonomous driving architecture,” featuring cameras, radar, lidar units, a high-grade computer and ultrasonic sensors. While many automakers already offer hands-free driving technology, Xpeng CEO, He Xiaopeng, said that they are the first company to offer lidar sensors on a production model, and the architecture as a whole will allow users to hands-free driving in low-speed urban settings. Looking ahead, the future could be bright for the company. Though fears about the risks posed by China’s political makeup are valid, they also assist the EV growth situation. With the country keen to reduce its oil and gas import costs and forecast fossil fuel usage expected to be down 70% by 2030, the future of transport seems to be swinging decisively in favour of electric vehicles. Chinese EV sales were up by 12.5% year-on-year in October, and there will be hopes that Trump trade war conditions will subside once Biden takes office next January (though BlackRock remain sceptical on this). Xpeng also benefits from having an ambitious CEO, He Xiaopeng, who sold his last company for $4 billion back in 2014, and, having taken charge of Xpeng back in 2017, now enjoys the backing of e-commerce giant, Alibaba. What really matters, though, will be whether Xpeng can maintain its growth, or whether it’s just a flash in the pan. Having seen its share price rise from $0.20 to over $66 between September and November, the company is off to a strong start. We have to stress though, this is just the ‘start’. Performance and projections remain strong, but consumer attitudes can change on a dime (especially in a trendy theme like EVs), and there is always risk when investing in a Chinese company, listed in New York. With that being said – if the company emulates the Tesla or NIO rally, it will be a haymaker for its early backers.

AA shares down as firm mulls private equity takeover

Shares at roadside recovery firm AA plc (LON:AA) were down almost 5% on Monday evening as Sky News reported that the company’s board is set to recommend a private equity takeover to help reduce its £2.6 billion debt mountain. The motoring group is reportedly being considered for a £218 million takeover proposal from TowerBrook Capital Partners and Warburg Pincus, with both firms offering to pay 35p a share and invest an additional £380 million to put towards paying off AA’s outstanding debt. To put that into context, when AA first floated the stock market in 2014, its shares stood at 250p and its total share value stood at about £1.4 billion. According to UK takeover rules, a deal must be reached by 5pm on Tuesday. It is understood that Rick Haythornthwaite – former chairman of British Gas owner Centrica – will chair the AA following the acquisition. He also currently chairs Mastercard and the Creative Industries Federation. The AA said in a statement to The Guardian: “The board, having considered carefully the viability of a range of alternative potential debt and equity refinancing options together with its financial advisers, has indicated to the consortium that it would be willing to recommend a cash offer on the terms of the proposal. Accordingly, the company is engaged in advanced discussions with the consortium in relation to the possible offer”. Across its almost 3 million members, Basingstoke-based AA was launched in 1905 as the Automobile Association and once styled itself as the UK’s “fourth emergency service”. The firm boasts 3,000 patrol vehicles and primarily provides roadside assistance, as well as home and car insurance, and driving lessons. AA shares were not impressed by the news on Monday, down 4.77% to 31.95p at the market’s close 23/11/2020, although a marked improvement from the company’s annual nadir of just 13.52p during February. Over the course of the year, shares have taken a 28.46% blow, but recent gains in the past month sent prices up 31.83% again. Its P/E ratio stands at 2.38 and its dividend yield a modest 1.88%.      

Gold tumbles to 4-month low after strong U.S. data, vaccine progress

The price of gold fell nearly 2% to a 4-month low on Monday after better-than-expected U.S. business activity data and optimism over the progress in Covid-19 vaccine development sent investors turning away from their safe haven assets, as hopes mount that a swift economic recovery may be on the horizon. Spot gold dipped 1.68% to $1,839.73 per ounce, after slipping to its lowest since July 21 at $1,834.95, while U.S. gold futures shed 2% to $1,835.50. Stock markets bounced on the news that U.S. business activity increased at its fastest rate in 5 years during November, topping even the most rosy forecasts from Reuters, and spurred investors to inch away from gold after a year which saw the precious metal revel in its all-time high during the peak of the pandemic. Meanwhile, across the pond in the UK, the joint AstraZeneca-Oxford University coronavirus vaccine programme published its first results, showing that their jab can provide upwards of 70% immunity against Covid-19. Investors hoping for it to outdo competitors’ immunity rates were initially disappointed, but news of another victory in the fight against the pandemic continued to buoy markets higher. Edward Moya, senior market analyst at OANDA, commented on how today’s updates have affected gold prices: “Gold broke below the key $1,850 level after an unbelievably strong U.S. PMI release just dampened the need for stimulus. No one was expecting such strong readings in both services and manufacturing”. Weighing in on what this all means for gold in the coming weeks, Axi chief global market strategist, Stephen Innes, explained to Investing.com: “Despite all the dovish FED waxing, gold is still trying to form a base after the $100 drop two weeks ago on the back of Pfizer vaccine news. Given it has bounced off $1,850 about three times, there should be a fair amount of speculative interest around that level, and it might be safe to assume a sharp move lower should it break. “There is still a lot of wood to be chopped to take out strategic longs. Those investors hold gold on a more medium-term basis, given considerable fiscal and monetary spending across G10 economies. “The only short-term potential trigger for a move higher might be the announcement of a new Treasury Secretary by US President-elect Joe Biden, with former Fed chair Janet Yellen being favored at the moment and the restart of discussions regarding a second US stimulus package”.

What Are the Top Penny Stocks to Watch Moving Into 2021?

SMEs with stock offerings that trade under $5 per share are regarded as penny stocks by the SEC (Securities and Exchange Commission) in the US. In the United Kingdom, penny stocks trade at less than £1. These ‘penny stocks’ companies are characterized by low market capitalizations, and their share offerings are usually associated with low trading volumes. Given that they are usually in their infancy stage of development, they don’t have mass market exposure, and they typically fly under the radar. Penny stocks are often traded over-the-counter (OTC), or as Pink Sheets. This has important ramifications in terms of credibility. Securities and Exchange Commission (SEC) guidelines, and Financial Conduct Authority (FCA) guidelines have strict rules in place vis-a-vis reporting requirements for listed companies. In the absence of listings on the NASDAQ, S&P 500, NYSE, or LSE, traders have to be careful when picking penny stocks. Fortunately, there are 4 different tiers of penny stocks to choose from, most significantly Tier 1 Stocks and Tier 2 Stocks. An in-depth education is needed to successfully trade penny stocks online. This guide presents several penny stocks to watch for November 2020.

FindIt Inc (OTCPK: FDIT)

  The above chart reflects the current demand/supply, and attendant pricing for Findit Inc (FDIT). The stock is currently regarded as neutral, but recent performance has been strongly bullish heading towards the end of November. The company has a low market cap, as indicated by its $13.581 million figure. The stock is currently trading at $0.1150, almost 4 times higher than it started the year ($0.0318) on January 1, 2020. Tremendous volatility was evident heading into October, and again heading into November. Traders ran up the price of the stock to over $0.20 per share, before taking profit. The charts and patterns reflect this bullish trading activity, and attendant profit-taking. When traders sold off en masse, the price dropped, allowing for additional price action to buy the dip. That caused the price to rally again. The current pricing for FindIt– an app that has been approved for the Google Play Store – as indicated by the Bollinger Bands is neutral. The stock has a 50-day moving average of $0.11, and a longer term 200-day moving average of $0.06. The current Bollinger Bands have a high band of $0.18, a median band of $0.13, and a low band of $0.09. The price is currently a sliver beneath the median band, indicating that it is possibly slightly oversold and ripe for a reversal.

Bantec Inc (OTCPK: BANT)

  Bantec Inc is another penny stock that trades OTC. This products & services company manufactures hand sanitizers, and disinfectants. The stock is currently priced at $0.0025 with negligible overall price movement for the year-to-date. There were several periods of volatility over the past month where the stock rallied tremendously. For example, in the final days of October, Bantec stock hit a price of $0.066, which is 2.5 times its current trading price. While miniscule in nominal terms, this huge price percentage appreciation represents a dramatic opportunity for penny stocks traders.
Source: Yahoo Finance
This underscores the importance of percentage appreciation, versus price appreciation. Penny stocks traders who invested $1000 in BANT on October 27 at a price of $0.0031 would have seen the valuation of that stock increased to $0.066 by October 28, before the sell-off and take profit orders were exercised. The initial purchase was the equivalent of 322,580 shares which could have been sold for $0.0066, for a price of $2,129, netting a profit of $1,129.

Digital Ally Inc (NASDAQ: DGLY)

 
Source: Stocktwits
Digital AllyIncorporated manufactures body cameras for the police department, among others. The stock is currently trending bearish, as evidenced by the recent downturn since early November. At its current price point ($2.29) it qualifies as a penny stock, and it is listed on the NASDAQ. This automatically places it as a Tier 1 category penny stock since it is subject to stringent reporting requirements. There has been substantial price movement in the stock over the past month, with lows of $1.95 and highs of $3.120. The company’s market capitalization is $61.309M, and the 1-year target estimate is $5.00 per share. When trading the stock, several important figures need to be assessed, notably the actual earnings versus the consensus earnings. In Q2 2020, and Q3 2020, DGLY beat expectations. This bodes well for bullish trading movements with the stock. The last major ratings upgrade & downgrade by Aegis Capital recommended a buy for this stock. In terms of long-term propositions, with a Biden administration in place, and greater accountability expected of the police force, we can expect demand for DGLY to increase. By the same token, a diminished police presence may act against the stock’s appreciation. It’s too early to tell which way to trade this penny stock, but a buy and hold for the foreseeable future appears to be the consensus. Note: It is foolhardy to simply accept expert opinions regarding top listings of penny stocks to trade, without conducting your own due diligence. Recommended stocks may be good at the time of writing, but by the time you have read the article, other stocks may be preferred.

Air travel, financial and commodities stocks soar on AstraZeneca vaccine news

Shock, the third Monday in a row where vaccine news push value stocks higher. Though underwhelming, the AstraZeneca (LON:AZN) vaccine trial results shoved long-suffering air travel, financial and commodities stocks higher, once again. Across the FTSE 100, air travel stocks led the way, with Rolls Royce soaring 7.60%, while IAG bounced around 5.50%. Meanwhile, mining and oil stocks stole the show. While Glencore and BHP rallied 2.37% and 2.25% apiece, BP jumped 3.70% and Shell shares spiked around four-and-a-half percent. Enjoying some progress, too, were financial services equities, with Lloyds rallying 3.87% while Aviva shares increased by 2.08%. After three weeks of waiting to see where vaccine competitors stand, AstraZeneca’s latest round of results will provide a short boosts ahead of the yet-to-be-published Janssen trial data. For now, IG Senior Market Analyst, Joshua Mahony, goes over the somewhat muted update: “With AstraZeneca 2% down in early trade, it is evident that markets are somewhat underwhelmed after the largest of the two trials providing just a 70% efficacy.” “Unfortunately for AstraZeneca, markets have become accustomed to efficacy rates closer to 95% in the wake of the Pfizer and Moderna announcements.” “While the firm has understandably focused on the 90% efficacy rate seen when a half dose is followed by a full dose a month later, the significantly reduced sample size does provide less confidence in their findings.” Though a break from lockdown and the reopening of non-essential shops over Christmas has given some a boost, the disappointing AstraZeneca vaccine data has left European equities in a huff as trading came to a close on Tuesday. Eurozone indexes remained broadly flat, with the DAX down 0.078% while the CAC fell by 0.068%. Meanwhile, the FTSE led the Western losers, falling 0.28% despite positive movements in air travel, financial and commodities equities. Over the pond, the Dow Jones rallied by 0.67%, while the Nasdaq edged lower with a 0.014% loss.

Unilever or Diageo – which consumer giant should be your portfolio bedrock?

2
Hit hard during the pandemic, these consumer conglomerates are ideal picks for the old investment adage: buy into what you actually use. And indeed, you’d likely lead a pretty sheltered existence if you hadn’t stumbled across either a Unilever (LON:ULVR) or Diageo (LON:DGE) product. Using the Warren Buffet philosophy of buying into ‘exceptional companies’ – such as his own Berkshire Hathaway – a doubtful, long-term investor can do little better than tucking money into a company which produces a lot of very popular products. But the question that needs to be asked is – of these, which is best?

Two companies, hundreds of brands

The first area of comparison is their brands, which sectors they operate within, and the forecasts for what these areas look like. On the one hand, Unilever owns brands across homecare, beauty products and foods and beverages, including: Ben and Jerry’s, Knorr, Dove, Bovril, Carte D’Or, Alberto Balsam, Colman’s, Domestos, Lipton, Cif, Hellman’s, Lynx/Axe, Comfort, Persil, Matey, Magnum, Toni & Guy, Sure, Surf, Pure Leaf, Cornetto, Marmite, Radox, Simple, Solero, TRESemme, VO5, Vaseline, Wall’s, Vienetta, PG Tips, Pot Noodle (etc etc). In effect, they produce most of the products on your corner shop’s shelves. While sales have been ahead of target during 2020, uncertainty has continued to weigh on the company’s share price. Though, while tight purses might affect the extent of purchases in non-essential consumables, a lot of Unilever products in beauty and homecare will be viewed as shopping basket staples, and therefore would likely not be hampered too greatly, even in a COVID risk worst-case-scenario. On the other hand, we have the alcoholic beverages-specialised Diageo, which owns brands such as: Black & White, Johnnie Walker, J&B, Lagavulin, Singleton, Talisker, and Crown Royal whiskies; Ciroc, Ketel One, and Smirnoff vodkas; Bundaberg, Captain Morgan, and Ron Zacapa rums; Gordon’s and Tanqueray gins; as well as prolific names such as Don Julio tequila, Baileys liqueur and Guinness beer. With the international closure of hospitality outlets across the world, out-and-about alcoholic beverage sales have been absolutely hammered during 2020. With this painful fall, there are two avenues to consider going forwards. Following its recent share price dip, we might conclude that COVID risk factors will likely prevail until a vaccine is rolled out effectively – and will continue to weigh on sales. On the other hand, shares rallied in early November, and we might imagine that between being among the worst-affected sectors by the virus, and the pent-up demand for socialising and holidaying, the outlook for Diageo could be promising. Indeed, hopes of normality returning aside – Christmas is coming, and we have to consider how much holiday booze demand has already been priced in by the market.

Which one offers better value?

The second comparison should be on each company’s price, value and income potential. In terms of share price, both companies have been broadly moving upwards since the start of the first COVID lockdown, with both falling slightly on Monday, with Unilever down 1.68% and Diageo falling 0.91%, to 4,381p and 2,920p respectively. Analysts have a consensus ‘Hold’ stance on Unilever stock, with 6 Buy, 2 Hold, and 3 Sell stances. Similarly, the company has a consensus target price of 4,819.55p (around a 10% potential increase), with highs of 5,411p from Goldman Sachs analysts and lows of 3,814p courtesy of HSBC – both quoted in October. Meanwhile, analysts also have a ‘Hold’ stance on Diageo stock, with 10 Buy, 6 Hold and 2 Sell stances. Its consensus target price is 2,969p, some 1.7% up from its current level and contrasting Goldman Sachs’ November target projection of 3,200p, and UBS’ September projection of 2,800p. In terms of which is better, Diageo received a 56.64% ‘outperform’ prediction from the Marketbeat community, versus Unilever’s 52.27% ‘underperform’ vote share. However, each company has appeared in seven research reports over the last three months – which suggests high interest in both – while Unilever insiders have sold none of the company’s stock in the last ninety days, whereas Diageo insiders sold 1,153% more of the company’s stock than they bought. This follows Diageo’s recent share price uptick, where it bounced around 530p. And, while selling off stock to capitalise on a boom isn’t inherently negative, it does suggest that insiders found short term maximisation more worthy than the company’s price prospects in the short-to-medium-term. Meanwhile, at its lowest since the start of the month, Unilever stock has been described by many on forums as a bargain. In terms of value, Unilever also outperforms Diageo. Its p/e ratio of 17.44 is still above the consumer defensive average of 11.49, but far far below Diageo’s 48.99 score. The story is much the same in terms of income. Unilever boasts a 3.42% dividend yield and a pay-out ratio of 59.27%. Being below 75% or so, this rate stands at a healthy and sustainable level. In contrast, Diageo has a dividend yield of 2.40%. Not shabby, but its pay-out ratio of 116.86% isn’t ideal, as it may be too high to be sustainable – and relied upon.

A mind towards posterity

Our final consideration, which is natural when thinking of a long-term holding, is future strategy and product considerations. In reality, both companies excel in innovation, with both featuring highly trendy brands who capitalise on consumer whims and cultural events. For instance, Unilever’s Ben & Jerry’s creates new flavours to tap into contemporary tropes (such as Netflix and Chill’d), and performs vocal advocacy on issues such as climate change, BLM and the migrant/refugee crisis (not interchangeable, just depends on the viewer). Meanwhile, Diageo is hardly slacking, having launched the Johnnie Walker ‘White Walker’ to mark the Game of Thrones finale, along with new gin flavours, no-ice-needed Baileys, and a fruit-based Ketel One variety, to adapt with changing consumer taste trends. In terms of their commitments to sustainability, both companies have set clear targets, with Diageo pledging to be carbon neutral by 2030, while Unilever has for some time reported on its sustainability initiatives, and now targets $1.2 billion in plant-based sales by 2025. Likely the more ambitious in terms of sustainability goals, Unilever’s push for greener mass production is positive overall – with sustainability being an increasingly factored-in part of the investment process. However, it will alienate some who view this kind of overt messaging to be contrary to their own views – or, ‘virtue signalling’. Out of the two companies, I’d favour Unilever. Its recovery may not be as dramatic as the one Diageo saw a couple of weeks ago (and may yet see), but its current entry point is comfortable versus where it is expected to move over the coming years. Similarly, it’s less overvalued, pays a bigger dividend and seems to be more decisive in its green transition. For full disclosure, the author has a holding in Unilever, but this was only after beginning to carry out his research into different consumer defence equities.